B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

MacroGenics, Inc.

MacroGenics, Inc.

MGNX

0.00

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ: MGNX) with a Buy and raises the price target from $9 to $11.